Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Acupuncture needles may boost immunotherapy in tough lung cancer cases

NCT ID NCT07239661

First seen Nov 20, 2025 · Last updated Jun 19, 2026 · Updated 28 times

Summary

This study tests whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to standard immunotherapy can help people with advanced non-small cell lung cancer who are too weak for aggressive treatment. About 120 participants will receive either real or sham electroacupuncture alongside their PD-1 inhibitor drugs. Researchers will track how long they live without the cancer getting worse, their quality of life, and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

    RECRUITING

    Tianjin, Tianjin Municipality, 300193, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

electroacupuncture

What this could lead to

If it works, this could show that adding electroacupuncture to immunotherapy helps people with advanced lung cancer live longer and feel better.

What could go wrong

This is an early-stage trial with no phase designation, so results are uncertain. The sham control group may also show benefits, and the small sample size limits general conclusions.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.